Long-term results of glaucoma drainage device surgery.


Journal

BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802

Informations de publication

Date de publication:
10 Jan 2019
Historique:
received: 10 01 2018
accepted: 02 01 2019
entrez: 12 1 2019
pubmed: 12 1 2019
medline: 27 1 2019
Statut: epublish

Résumé

To evaluate long-term results of eyes with glaucoma drainage device (GDD). We retrospectively reviewed medical records of all patients who underwent GDD placement at our institution between 2001 and 2014. A total of 110 eyes of 90 patients were studied. Glaucoma outcome was assessed by postoperative intraocular pressure (IOP), number of medications, and need for further glaucoma surgery. Surgical procedures before and during the study period, and their complications were evaluated. The mean follow-up was 78.3 ± 44.0 months. The mean preoperative intraocular pressure was 30.8 ± 6.9 mmHg with 3.5 ± 1.1 glaucoma medications. At last postoperative follow-up, the mean IOP decreased to 14.3 ± 5.4 mmHg with 1.6 ± 1.5 glaucoma medications. GDD implantation successfully controlled glaucoma in 86, 85, 81, 78, 79, 76 and 73% of eyes at 1, 2, 3, 4, 5, 7 and 10 years, respectively. At last follow-up IOP was successfully controlled in 67% of eyes. Clinical complications occurred in 56.4% of eyes during the follow-up period. A glaucoma drainage device can successfully control intractable glaucoma even after a very long period of time.

Sections du résumé

BACKGROUND BACKGROUND
To evaluate long-term results of eyes with glaucoma drainage device (GDD).
METHODS METHODS
We retrospectively reviewed medical records of all patients who underwent GDD placement at our institution between 2001 and 2014. A total of 110 eyes of 90 patients were studied. Glaucoma outcome was assessed by postoperative intraocular pressure (IOP), number of medications, and need for further glaucoma surgery. Surgical procedures before and during the study period, and their complications were evaluated.
RESULTS RESULTS
The mean follow-up was 78.3 ± 44.0 months. The mean preoperative intraocular pressure was 30.8 ± 6.9 mmHg with 3.5 ± 1.1 glaucoma medications. At last postoperative follow-up, the mean IOP decreased to 14.3 ± 5.4 mmHg with 1.6 ± 1.5 glaucoma medications. GDD implantation successfully controlled glaucoma in 86, 85, 81, 78, 79, 76 and 73% of eyes at 1, 2, 3, 4, 5, 7 and 10 years, respectively. At last follow-up IOP was successfully controlled in 67% of eyes. Clinical complications occurred in 56.4% of eyes during the follow-up period.
CONCLUSIONS CONCLUSIONS
A glaucoma drainage device can successfully control intractable glaucoma even after a very long period of time.

Identifiants

pubmed: 30630462
doi: 10.1186/s12886-019-1027-z
pii: 10.1186/s12886-019-1027-z
pmc: PMC6327392
doi:

Substances chimiques

Antihypertensive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

14

Références

Curr Opin Ophthalmol. 1999 Apr;10(2):147-53
pubmed: 10537766
Ophthalmology. 2001 Jun;108(6):1050-8
pubmed: 11382628
J Glaucoma. 2001 Oct;10(5 Suppl 1):S73-5
pubmed: 11890285
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
pubmed: 12049574
Ophthalmology. 2004 Jul;111(7):1383-8
pubmed: 15234141
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
Curr Opin Ophthalmol. 2006 Apr;17(2):181-9
pubmed: 16552254
Clin Exp Ophthalmol. 2006 Mar;34(2):102-7
pubmed: 16626421
Ophthalmology. 2006 Jun;113(6):913-7
pubmed: 16751034
Ophthalmology. 2007 Dec;114(12):2265-70
pubmed: 17466376
Ophthalmology. 2007 Nov;114(11):1965-72
pubmed: 17628686
Am J Ophthalmol. 2007 Dec;144(6):893-900
pubmed: 17916318
Curr Opin Ophthalmol. 2012 Mar;23(2):118-26
pubmed: 22249235
J Glaucoma. 2015 Feb;24(2):95-9
pubmed: 23787335
Ophthalmology. 2013 Nov;120(11):2232-40
pubmed: 23796764
Ophthalmology. 2015 Feb;122(2):308-16
pubmed: 25439606
Ophthalmology. 1994 Apr;101(4):640-50
pubmed: 8152758

Auteurs

Konstantine Purtskhvanidze (K)

Department of Ophthalmology, University Medical Center Schleswig-Holstein, Arnold-Heller Strasse 3, Haus 25, D-24105, Kiel, Germany. konstantine.purtskhvanidze@uksh.de.

Mark Saeger (M)

Department of Ophthalmology, University Medical Center Schleswig-Holstein, Arnold-Heller Strasse 3, Haus 25, D-24105, Kiel, Germany.

Felix Treumer (F)

Department of Ophthalmology, University Medical Center Schleswig-Holstein, Arnold-Heller Strasse 3, Haus 25, D-24105, Kiel, Germany.

Johann Roider (J)

Department of Ophthalmology, University Medical Center Schleswig-Holstein, Arnold-Heller Strasse 3, Haus 25, D-24105, Kiel, Germany.

Bernhard Nölle (B)

Department of Ophthalmology, University Medical Center Schleswig-Holstein, Arnold-Heller Strasse 3, Haus 25, D-24105, Kiel, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH